These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37667289)

  • 1. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
    Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
    Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
    Brouillard P; Schlögel MJ; Homayun Sepehr N; Helaers R; Queisser A; Fastré E; Boutry S; Schmitz S; Clapuyt P; Hammer F; Dompmartin A; Weitz-Tuoretmaa A; Laranne J; Pasquesoone L; Vilain C; Boon LM; Vikkula M
    Orphanet J Rare Dis; 2021 Jun; 16(1):267. PubMed ID: 34112235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS).
    Vahidnezhad H; Youssefian L; Uitto J
    Exp Dermatol; 2016 Jan; 25(1):17-9. PubMed ID: 26268729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of next generation sequencing-liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel-Trenaunay syndrome.
    Palmieri M; Pinto AM; di Blasio L; Currò A; Monica V; Sarno LD; Doddato G; Baldassarri M; Frullanti E; Giliberti A; Mussolin B; Fallerini C; Molinaro F; Vaghi M; Renieri A; Primo L
    Vascular; 2021 Feb; 29(1):85-91. PubMed ID: 32588787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
    Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
    J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
    Pirozzi F; Berkseth M; Shear R; Gonzalez L; Timms AE; Sulc J; Pao E; Oyama N; Forzano F; Conti V; Guerrini R; Doherty ES; Saitta SC; Lockwood CM; Pritchard CC; Dobyns WB; Novotny E; Wright JNN; Saneto RP; Friedman S; Hauptman J; Ojemann J; Kapur RP; Mirzaa GM
    Brain; 2022 Apr; 145(3):925-938. PubMed ID: 35355055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response.
    Engel ER; Hammill A; Adams D; Phillips RJ; Jeng M; Tollefson MM; Iacobas I; Schiff D; Greenberger S; Kelly M; Frieden I; Zaghloul N; Drolet B; Geddis A; Goldenberg D; Ricci K
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30215. PubMed ID: 36651691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway.
    Hori Y; Hirose K; Aramaki-Hattori N; Suzuki S; Nakayama R; Inoue M; Matsui T; Kohara M; Toyosawa S; Morii E
    Diagn Pathol; 2020 Jul; 15(1):98. PubMed ID: 32711543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
    Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
    Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wound-Healing Problems Associated with Combined Vascular Malformations in Klippel-Trenaunay Syndrome.
    Ishikawa K; Yamamoto Y; Funayama E; Furukawa H; Sasaki S
    Adv Wound Care (New Rochelle); 2019 Jun; 8(6):246-255. PubMed ID: 31832274
    [No Abstract]   [Full Text] [Related]  

  • 13. PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.
    Guan R; Kang Z; Li L; Yan X; Gao T
    PLoS One; 2024; 19(1):e0295813. PubMed ID: 38194422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Custom Pediatric Oncology Next-Generation Sequencing Panel Identifies Somatic Mosaicism in Archival Tissue and Enhances Targeted Clinical Care.
    Quindipan C; Cotter JA; Ji J; Mitchell WG; Moke DJ; Navid F; Thomas SM; VanHirtum-Das M; Wang L; Saitta SC; Biegel JA; Hiemenz MC
    Pediatr Neurol; 2021 Jan; 114():55-59. PubMed ID: 33221597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined capillary-venous-lymphatic malformations without overgrowth in patients with Klippel-Trénaunay syndrome.
    Brandigi E; Torino G; Messina M; Molinaro F; Mazzei O; Matucci T; López Gutiérrez JC
    J Vasc Surg Venous Lymphat Disord; 2018 Mar; 6(2):230-236. PubMed ID: 29233587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploinsufficiency of Klippel-Trenaunay syndrome gene Aggf1 inhibits developmental and pathological angiogenesis by inactivating PI3K and AKT and disrupts vascular integrity by activating VE-cadherin.
    Zhang T; Yao Y; Wang J; Li Y; He P; Pasupuleti V; Hu Z; Jia X; Song Q; Tian XL; Hu C; Chen Q; Wang QK
    Hum Mol Genet; 2016 Dec; 25(23):5094-5110. PubMed ID: 27522498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum.
    Michel ME; Konczyk DJ; Yeung KS; Murillo R; Vivero MP; Hall AM; Zurakowski D; Adams D; Gupta A; Huang AY; Chung BHY; Warman ML
    Clin Genet; 2018 May; 93(5):1075-1080. PubMed ID: 29231959
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.